Innocan Pharma Corporation announced the results of a recent tissue distribution study of its liposome CBD platform (LPT-CBD), that indicated the potential of LPT-CBD to support a new therapeutic venue for neurological disorders. The fundamentals of Innocan's LPT-CBD platform lay in its ability to slowly-release CBD into the blood stream following a single subcutaneous injection. Recent pharmacokinetic studies conducted in various animal models, including mice, dogs, goats and sheep, showed long exposure of CBD that persisted up to several weeks.

In the Company's latest study, CBD was found to be in the brains of both mice and rabbits weeks after LPT-CBD was subcutaneously injected to them. These results show a strong correlation between the prolonged blood exposure of CBD and its brain distribution. LPT technology provides a long presence of CBD in the blood enabling CBD to pass the blood brain barrier (B.B.B) and deliver long brain exposure.

Sufficient exposure of CBD in the brain is the hallmark of CBD therapy associated with various neurological conditions. During these studies, LPT-CBD was injected subcutaneously in rabbits and mice. CBD concentrations in the blood of these animals were followed for a period of 11 and 22 days respectively.

At the end of the study, the CBD levels were evaluated in their brains to find a correlation between the observed long pharmacokinetics of LPT-CBD and its actual tissue distribution. As expected, CBD was detected in the animals' blood for several weeks. More importantly, a significant level of CBD was revealed in their brain, supporting a prolonged CBD brain distribution via LPT-CBD delivery.

Cannabidiol has demonstrated positive effects in association with various neurological disorders. Besides its well-established anti-epileptic activity, CBD can also protect brains pathology via the activation of anti-inflammatory and antioxidant mechanisms. For example, CBD was demonstrated to efficiently protect brain cells from Alzheimer-induced degeneration, reducing the onset of the diseases. In addition, CBD can protect from damage that occurs following an ischemic brain stroke leading to better tissue regeneration and patient recuperation.

CBD was shown to have strong beneficial effects in other neurological conditions such as autism or schizophrenia emphasizing its high contribution in improving behavioral impairment usually associated with such pathologies. The fact that LPT-CBD successively delivers CBD to the brain in a long-lasting manner opens a big venue for the treatment of various neurological disorders.